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A B S T R A C T
Introduction. Gay men with prostate cancer (GMPCa) may have differential health-related quality of life (HRQOL)
and sexual health outcomes than heterosexual men with prostate cancer (PCa), but existing information is based on
clinical experience and small studies.
Aims. Our goals were to: (i) describe HRQOL and examine changes in sexual functioning and bother; (ii) explore
the psychosocial aspects of sexual health after PCa; and (iii) examine whether there were signiﬁcant differences on
HRQOL and sexual behavior between GMPCa and published norms.
Methods. A convenience sample of GMPCa completed validated disease-speciﬁc and general measures of HRQOL,
ejaculatory function and bother, fear of cancer recurrence, and satisfaction with prostate cancer care. Measures of
self-efﬁcacy for PCa management, illness intrusiveness, and disclosure of sexual orientation were also completed.
Where possible, scores were compared against published norms.
Main Outcome Measures. Main outcome measures were self-reported sexual functioning and bother on the
Expanded Prostate Cancer Index.
Results. Compared with norms, GMPCa reported signiﬁcantly worse functioning and more severe bother scores on
urinary, bowel, hormonal symptom scales (Ps < 0.015–0.0001), worse mental health functioning (P < 0.0001), greater
fear of cancer recurrence (P < 0.0001), and were more dissatisﬁed with their PCa medical care. However, GMPCa
reported better sexual functioning scores (P < 0.002) compared with norms. Many of the observed differences met
criteria for clinical signiﬁcance. Physical functioning HRQOL and sexual bother scores were similar to that of
published samples. GMPCa tended to be more “out” about their sexual orientation than other samples of gay men.
Conclusions. GMPCa reported substantial changes in sexual functioning after PCa treatment. They also reported
signiﬁcantly worse disease-speciﬁc and general HRQOL, fear of recurrence, and were less satisﬁed with their
medical care than other published PCa samples. Sexual health providers must have an awareness of the unique
functional and HRQOL differences between gay and heterosexual men with PCa. Hart TL, Coon DW,
Kowalkowski MA, Zhang K, Hersom JI, Goltz HH, Wittmann DA, and Latini DM. Changes in sexual roles
and quality of life for gay men after prostate cancer: Challenges for sexual health providers. J Sex Med
2014;11:2308–2317.
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Introduction
Gay men represent at least 3% of the malepopulation in the United States [1],
although this may be a large underestimation of
the broader category of men who have sex with
men, but do not self-identify as gay [2]. Indeed,
Blank suggested that at least 5,000 gay men
develop prostate cancer (PCa) each year; more-
over, at least 50,000 gay men are PCa survivors in
the United States. [3]. Some researchers have
proposed that gay men’s experience of PCa may
differ fundamentally from that of heterosexual
men [4].
Until recently, data have been quite limited on
health-related quality of life (HRQOL) in gay men
with prostate cancer (GMPCa). A pilot study of 15
men treated with radiation or surgery reported
lower scores on the urinary and bowel domains of
the Expanded Prostate Cancer Index Composite
(EPIC) and the ejaculatory function and bother
scores [5]. In another small study, gay men under-
going anti-androgen treatment reported worse
scores on the International Index of Erectile Func-
tion than heterosexual men receiving the same
treatment [6]. In a larger study, men in the United
States, Australia, Canada, United Kingdom, and
other countries reported no signiﬁcant differences
in sexual function scores between heterosexual
(N = 460) and nonheterosexual men (N = 96),
while nonheterosexual men reported signiﬁcantly
worse sexual bother, ejaculatory function, and
ejaculatory bother [7]. In an unpublished study,
gay men reported signiﬁcantly lower urinary and
bowel functioning than heterosexual men [8].
Treatment regret was higher in men with poorer
urinary and sexual functioning.
While sexual functioning data are mixed, there
may be sexual concerns faced only by gay men.
Erectile dysfunction (ED) treatments typically
focus on creating erections rigid enough for
vaginal penetration. However, anal penetration
requires a greater rigidity [9]. After anal penetra-
tion, the insertive partner also may have difﬁculty
maintaining their erections, if penetration forces
blood from the penis [9]. In addition, some gay
men report damage to the anus and rectum during
PCa treatment that makes receptive anal inter-
course painful or reduces the sensation [9]. In a
qualitative study, gay men without PCa were asked
about their attitudes toward PCa and PCa treat-
ment [10]. Ejaculation was described as crucial to
satisfying sex and maintaining relationships with
partners. Participants reported feeling disenfran-
chised by the emphasis on vaginal penetration in
ED treatment and research.
This sense of disenfranchisement and being
invisible can be seen in other ways. GMPCa may
be reluctant to disclose their sexual orientation to
a healthcare provider, precluding a partners’
involvement in treatment decision-making [11].
Stigma around homosexuality may be related to
negative experiences in the healthcare system,
such as providers failing to ask about sexual orien-
tation and assuming heterosexuality [11]. These
negative experiences with the healthcare system
are likely related to the poorer health outcomes
experienced by lesbian, gay, and bisexual persons
[12].
Many gay or bisexual men who are diagnosed
with PCa may be starting their cancer journey
from a much more vulnerable position than their
heterosexual counterparts and experience poorer
outcomes. However, empirical support for these
clinical and anecdotal claims is mixed. Therefore,
we carried out an Internet-based study of a con-
venience sample of GMPCa to determine the
extent to which study participants reported sig-
niﬁcantly different HRQOL and psychosocial
characteristics compared with published reports.
Based on our clinical experience, we expected
that GMPCa would report greater decrements in
sexual functioning and report being more both-
ered by these changes than the published data
from primarily heterosexual samples. We also
expected that GMPCa would report lower satis-
faction with their PCa treatment because of fre-
quent complaints by GMPCa participating in
support groups.
Materials and Methods
Study Population
We obtained institutional review board approval
from Baylor College of Medicine, Houston, TX,
USA and Ryerson University, Toronto, ON,
Canada. The eligibility criteria included: (i) self-
identiﬁcation as a gay or bisexual man; and (ii)
diagnosis of PCa in the prior 4 years. The time
period was selected to ensure participants had been
diagnosed and treated recently enough to accu-
rately report current HRQOL and recall changes
in sexual behavior since treatment. Given the difﬁ-
culty in recruiting this hard-to reach population,
recruitment methods included: postings to elec-
tronic listservs targeting PCa survivors, posting
ﬂyers in community centers and at support groups,
and advertising the study in the local media.
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Procedure
Interested participants called the study’s toll-free
number and underwent a brief phone-based
screening interview to determine eligibility.
Verbal informed consent was obtained after
screening, and eligible participants were e-mailed
a unique identiﬁcation code and a link to the
web-based survey. Online data were collected via
a web survey site that used the same secure-
socket layers technology as used in electronic
commerce. No names or other identifying infor-
mation were collected online. All data were col-
lected by self-report. Each participant received
$20 for completing the survey.
Instruments
Demographic and Medical Information
Demographic information (age, ethnicity, educa-
tion, nationality, education level) and medical
characteristics (PSA level, Gleason score, PCa
treatment, T-stage at diagnosis, and comorbidities)
were assessed using the same questions as another
large PCa patient-reported outcome study [13].
Disease-Specific Quality of Life
The EPIC [14] was used to assess urinary, bowel,
sexual, and hormonal symptom frequency and per-
ceived bother. The scales have established test–
retest reliability (r ≥ 0.80) and internal consistency
(α ≥ 0.82) for the summary scores for each of the
four domains.
General HRQOL
The Physical Health Composite Scale and Mental
Health Composite Scale from the Medical Out-
comes Study Short Form-36 [15] (SF-36) were
used to measure HRQOL. These scales have well-
established reliability and validity [16].
Change in Sexual Activity
Three items assessed change in sexual activity
since PCa treatment. Participants rated: (i) the
extent to which their sexual behavior changed
(ranging from 1 = “decreased a lot” to 3 =
“increased a lot”); (ii) the frequency of being the
insertive partner for sexual activity (ranging from
1 = 0% to 4 = 100%) before PCa treatment; and
(iii) similarly, after PCa treatment. Men were also
able to indicate if they were not sexually active
before or after PCa treatment. As no previously
validated measures were available, we developed
these questions for this study.
Ejaculatory Function and Bother
Three items from the Male Sexual Health Ques-
tionnaire Short-Form (MSHQ) [17], which were
validated in several probability samples, some of
which included gay men, assessed the degree of
dysfunction in ejaculation ability, volume, and
strength. Items were summed to form an ejacula-
tory functioning score. Greater scores reﬂect
better function. The scale has established reliabil-
ity [17]. Another item assessed bother, ranging
from 0 = no problem with ejaculation to
5 = extremely bothered.
Satisfaction with PCa Care
One item on the EPIC [14] assessed “Overall, how
satisﬁed are you with the treatment you received
from your PCa,” which ranged from “extremely
dissatisﬁed” to “extremely satisﬁed.”
Self-Efficacy for PCa Symptom Management
Eleven items assessed the extent to which men felt
conﬁdent in controlling their PCa-related prob-
lems (e.g., urine leakage, understanding their
treatment), ranging from 1 = not at all certain to
5 = completely certain. Items are summed to form
a total score. The scale has established good inter-
nal consistency and has been shown to predict
HRQOL [18].
Disease-Specific Anxiety
Fear of cancer recurrence was measured with
Kornblith’s ﬁve-item scale used in the Cancer
of the Prostate Strategic Urologic Research
Endeavor (CaPSURE™) studies [13]. Raw scale
scores were reversed and transformed to a 0 to 100
scale, with higher scores reﬂecting greater fear of
recurrence. The reliability and validity of this scale
have been previously established [19].
Illness Intrusiveness Rating Scale (IIRS)
Illness intrusiveness refers to perceived disruption
from illness and treatment, and their impact on
valued life activities that affect HRQOL [20]. The
rating scale contains 13 questions that ask how
much one’s cancer interferes with a range of life
domains. Ratings range from 1 = “Not very much”
to 7 = “Very much.” The measure has been vali-
dated in a wide range of diseases and has shown
good psychometric properties [21].
Sexual Orientation Disclosure or
“Outness Level”
Ten items from the Outness Inventory [22]
assessed the degree to which men were open about
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their sexual orientation in various life domains
(e.g., family, everyday life). Each item is rated on a
seven-point scale ranging from 1 = person deﬁ-
nitely does not know about my sexual orientation
to 7 = person deﬁnitely knows about my sexual
orientation. All items are summed to form an
overall “outness” score. The scale has demon-
strated internal consistency [22].
Understanding of Changes in Sexual Functioning
In addition to the previously described validated
measures, we also asked respondents a single open-
ended question about their understanding of any
sexual changes. We were interested in learning
about the difﬁculties respondents faced in their
own words and to understand whether there were
aspects of the sexual changes not well character-
ized by the validated questionnaires. Our intention
was to supplement the quantitative survey data
with a brief opportunity to contextualize a respon-
dent’s experience. However, this was not a true
mixed-methods study.
Data Analyses
Quantitative data were analyzed with SPSS statis-
tical software Version 17 (IBM Corporation,
Armonk, NY, USA). Outcome variables were
deﬁned as each domain’s mean scores. To compare
our data with published data, we carefully selected
studies that contained similarly-aged men who had
been treated for PCa within a comparable time
frame. For example, comparisons on any EPIC
construct were made against the EPIC validation
cohort, who were approximately 2 years posttreat-
ment and had a mean age 67.2 years, with equal
numbers who received brachytherapy, external
beam radiation, radical prostatectomy, and hor-
monal therapy. Comparisons for the SF-36 and
fear of recurrence measures were made against the
CaPSURE™ cohort, which is a national, observa-
tional registry of 14,000 PCa patients recruited
from community and academic-based urology
practices. All scores were converted to T-values;
t-tests compared means and standard errors (SEs)
for the current sample against published studies.
As in prior studies, we considered HRQOL differ-
ences of 10 points or more to be clinically signiﬁ-
cant [23].
Responses to the open-ended question were
tabulated to learn how respondents described their
sexual difﬁculties. We report these qualitative
ﬁndings descriptively, rather than thematically,
because of the exploratory nature of this question
and the brief written responses it elicited.
Results
Table 1 lists demographic and medical information
for our sample. Mean age of participants (N = 92)
was 57.8 years. Most participants were located in
the United States, Caucasian, in partnered rela-
tionships, and had completed at least college/
university. At diagnosis, the average PSA level was
8.75 and mean Gleason score was 6.1. Common
PCa treatments included radical prostatectomy
(55.4%), external beam radiation (27.2%), and
anti-androgen therapy (25%). Table 1 shows the
most frequently self-reported comorbidities. The
mean time since diagnosis was 1.91 years
(SE = 0.15) and no data were collected on treat-
ment end date. No signiﬁcant differences on any
demographic, medical characteristic, or outcome
variable were found between U.S. and Canadian
participants.
Changes in Patterns of Sexual Functioning
The majority of participants (55.4%; Table 1)
reported substantial changes in sexual behavior
since PCa treatment, with 40.2% of men reporting
the frequency of sexual activity had decreased “a
lot.” Figure 1 compares the frequency of being the
insertive partner for intercourse before and after
PCa treatment. Most men reported substantial dif-
ferences between their pre- and posttreatment
sexual functioning. For example, among the men
reporting they were the insertive partner for inter-
course 100% of the time pretreatment, only about
40% said they were the insertive partner after
treatment and less than 20% reported being the
insertive partner 100% of the time.
Disease-Specific Quality of Life
Table 2 displays the mean scores and SEs for
GMPCa compared with published means and SEs
for each of the symptoms and psychosocial
outcome variables. GMPCa had worse functioning
and more severe bother scores compared with the
urinary, bowel, and hormonal symptom validation
data (Ps < 0.015–0.0001) [14]. As we expected,
GMPCa also reported worse sexual functioning
scores (P < 0.002) than other published samples
[14,17]. Contrary to our expectations, they did not
report signiﬁcantly worse sexual bother scores.
Compared with CaPSURE™ data, GMPCa
reported signiﬁcantly worse mental health func-
tioning (P < 0.0001) on the SF-36, but not physical
health functioning [24]. Moreover, GMPCa
reported signiﬁcantly higher fear of recurrence
(P < 0.0001) [19].
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We were unable to locate other published
studies of PCa patients for the MSHQ ejaculatory
functioning or bother scale scores. Mean ejacula-
tory bother scores on the MSHQ for GMPCa was
2.8 (SE = 0.16), which reﬂects a “moderate”
amount of bother. The mean MSHQ ejaculatory
functioning scale score was 4.5 (SE = 0.38), which
reﬂects very low levels of ejaculatory functioning
in GMPCa. In prior research, men with lower
urinary tract symptoms and benign prostatic
hyperplasia reported average ejaculatory function-
ing scores of 12.4 [17]. While not directly compa-
rable given that the latter sample did not have
PCa, the means vary by 8 points, suggesting a
clinically signiﬁcant difference [23].
Psychosocial Variables
Respondents reported being signiﬁcantly more
“out” about their sexual orientation to their family
and to the world at large (Table 2; both P < 0.05)
than gay men in other published samples [22]. PCa
symptom management self-efﬁcacy, illness intru-
siveness, and satisfaction with care were also exam-
ined. GMPCa rated their overall self-efﬁcacy for
PCa symptom management as a moderate amount
of conﬁdence (Table 3, no comparator data were
available for this measure). We examined their
self-efﬁcacy for producing an erection and for
having a satisfying sexual relationship. Both were
signiﬁcantly lower than their overall self-
conﬁdence in managing symptoms (Ps < 0.001).
Respondents indicated that PCa had a moderate
impact on their lives on the overall IIRS score and
on the questions about the respondents’ sex life.
The reported interference on the relationship with
a spouse or partner was small to moderate. A sub-
stantial minority of men reported being dissatis-
ﬁed (11.8%) or being “uncertain” if they were
satisﬁed (34.8%) with PCa treatment. Notably, the
percentage of men who reported that they were
“satisﬁed” with their PCa care (64.7%) was, as we
expected, comparatively lower than that described
in another study of surgical patients (84%) [25].
Open-Ended Responses Describing Sexual
Difficulties Posttreatment
Forty-ﬁve men responded to the optional question
about changes in sexual functioning after treat-
ment. In their written responses to the open-ended
question, men brieﬂy reported a variety of prob-
lems beyond erectile difﬁculties (Table 4). The
most common response to the question was simply
change in their erectile ability (49%). Responses
Table 1 Participant characteristics (N = 92)
Age (years)
N Mean (SE)
89 57.8 (0.97)
%
Nationality
United States 77 83.7
Canada 15 16.3
Relationship status
Married/living with partner 42 45.7
Primary partner 16 17.4
No primary partner 21 22.8
Dating one/more people 6 6.5
Separated/Divorced 2 2.2
Widowed 3 3.3
Education
<High school 1 1.1
High school degree 4 4.3
Some college 20 21.7
College/University 27 29.3
Graduate school 37 40.2
Ethnicity
African American 5 5.4
Asian 1 1.1
Caucasian 84 91.3
Other 2 2.2
Treatment
Prostatectomy 51 55.4
External radiation 25 27.2
Brachytherapy 7 7.6
Hormonal therapy 23 25.0
No treatment 8 8.7
Other treatment 6 6.5
Years since diagnosis
Mean (SE)
1.91 (0.15)
Clinical characteristics at diagnosis Mean (SE)
PSA level 75 8.75 (1.11)
Gleason score 61 6.1 (0.19)
T-Stage N %
Low (T1c-T2a) 39 70.9
Intermediate (T2b-T2c) 6 10.9
High (T3-T4) 10 18.2
Comorbid conditions
Arthritis 24 26.1
Diabetes 12 12.5
Cardiovascular disease 11 11.6
HIV 6 7
Changes in sexual behavior since PCa treatment
No change 7 7.6
Changed a little 13 14.1
Changed a lot 51 55.4
No sexual activity 16 17.4
Frequency of sexual activity after PCa treatment
No change 9 9.8
Changed a little 22 23.9
Changed a lot 34 37.0
No sexual activity 21 22.8
Change in frequency of sexual activity
Decreased a lot 37 40.2
Decreased a little 18 19.6
Increased a little 0 0.0
Increased a lot 1 1.1
PCa = prostate cancer; SE = standard error
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grouped in the “other” category included age con-
cerns and men indicating they did not know
what caused the change. Men reported painful
erections, climacturia, and low libido after treat-
ment (Table 5, quote 1). Others reported changes
in self-image (Table 5, quotes 2–3). Some men
reported changing their sexual repertoire in
response to their changed erectile ability, with
mixed results (Table 5, quote 4). Some men
reported that their partner was struggling with the
change in their relationship (Table 5, quote 5).
Several men reported that the lack of ejaculation
Figure 1 Change in sexual behavior before and after PCa treatment.
Table 2 Comparison of quality of life scores between current sample and published samples of men with prostate
cancer
Current sample Comparator sample
t-Score PN Mean (SE) N Mean (SE)
EPIC urinary
Function 90 67.2 (2.8) 252 86.5 (1.0) [14] 7.94 0.0001
Bother 90 68.9 (3.1) 252 75.8 (1.3) [14] 2.43 0.015
EPIC sexual
Function 89 38.7 (2.6) 252 29.5 (1.5) [14] 3.07 0.002
Bother 88 40.1 (3.6) 252 41.1 (1.9) [14] 0.26 0.79
EPIC bowel
Function 90 77.6 (2.2) 252 87.9 (0.9) [14] 5.30 0.0001
Bother 90 77.5 (3.0) 252 85.3 (1.2) [14] 2.92** 0.004
SF-36
MCS 86 43.9 (1.4) 730 51.9 (1.4) [24] 7.02 0.0001
PCS 86 48.3 (1.1) 730 48.9 (0.4) [24] 0.52 0.60
EPIC hormonal
Function 85 73.5 (2.4) 252 84.0 (1.0) [15] 4.80 0.0001
Bother 90 52.4 (2.1) 252 88.7 (0.9) [15] 18.95 0.0001
Fear of recurrence 91 49.2 (2.3) 333 20.0 (1.1) [25] 12.86 0.0001
Outness level
To family 90 5.7 (0.2) 414 5.21 (0.1) [22] 2.87 0.004
To world 79 4.7 (0.2) 414 5.07 (0.1) [22] 2.01 0.04
Total 79 4.9 (0.2) 223 4.90 (0.1) [22] 0.00 1.00
EPIC = Expanded Prostate Cancer Index Composite; MCS = Mental Health Component Score; PCS = Physical Health Component Score; SE = standard error;
SF-36 = Short-Form-36 Health Survey
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had a profound impact on their sexual experience
(Table 5, quote 6). While many of these responses
are similar to concerns expressed by heterosexual
men, it is important to document these issues
among G/B men and identify areas for future
research (e.g., partner concerns, changes from
insertive to receptive partner, etc.).
Discussion
The interest in GMPCa treatment outcomes has
grown since our data collection ended and other
studies are beginning to be published [5,7,8,26].
From our data and these other studies, several
patterns are emerging. First, gay men may be
diagnosed at younger ages in our study and others,
leaving a longer potential time to live with
treatment-related side effects [7]. Gay men
reported signiﬁcantly worse urinary and bowel
function across studies. Sexual functioning and
bother and hormonal functioning varied across
studies.While EPIC sexual functioning and bother
scores were mixed across studies, clear patterns
emerged around poorer ejaculatory functioning
and greater bother in gay men. Gay men also
reported some changes in sexual role (Figure 1);
however, some men indicated in their responses to
our open-ended question that such changes were
problematic, agreeing with responses from previ-
ous qualitative work that suggests that sexual repo-
sitioning may not be an option for some men [10].
Importantly, these similarities in results emerge in
spite of differences in study design. Because of
concerns about recall bias, our study only included
men who were within 4 years of diagnosis while
other studies enrolled men with substantially
longer times since diagnosis [7,8]. One study only
enrolled men 50 and older. Given the younger age
at which gay men may be diagnosed, we chose not
to have a minimum age for enrollment [27]. In
addition, other studies to date have primarily
focused on HRQOL. Our study includes both
HRQOL and other important psychosocial vari-
ables not found in other studies. These factors
increase the strength of our study, relative to others.
Given their generally worse HRQOL, it may
not be surprising that men in our sample reported
lower satisfaction with PCa medical care com-
pared with other PCa survivors. However,
comorbidity rates in this sample were comparable
Table 3 Mean score on other psychosocial variables
Variable Mean (SE)
Symptom management self-efficacy
Overall 3.5 (0.09)
Self-efficacy for producing an erection 2.7 (0.15)
Self-efficacy for having a satisfying sexual
relationship
3.0 (0.13)
Illness Intrusiveness Rating Scale
Overall 30.93 (2.09)
Intrusion on sexual life 4.74 (0.25)
Intrusion on relationship with spouse or partner 2.49 (0.27)
SE = standard error
Table 4 Frequency of categories of responses (total sum
to more than 100% because of multiple responses by the
same individual)
Category N Percentage
ED 22 49
Other 9 20
MH 9 20
Partner 8 18
Desire 8 18
Climacturia 4 9
Pain 4 9
Ejaculation 1 2
N = 45
ED = erectile dysfunction; MH = mental health
Table 5 Selected verbatim responses to an open-ended
question about changes in sexual functioning after
prostate cancer treatment
1. My desire for sex has decreased, My penis feels numb most
of the time probably due to the androgen deprivation therapy
and I have a very difficult time having an orgasm. Also, it feels
funny when I have an orgasm, sometimes it would ache and
hurt in the area of my prostate for several days after an
orgasm.
—Respondent 110, 58-year-old treated with external beam
radiation and hormonal therapy
2. Due to surgery, much of the function has affected. The surgery
removed seminal vesicles so no longer was able to ejaculate. I
think it had a big impact on my self-confidence and very
stressed so often too uncomfortable and nervous to try to
have sex. Also urine leakage is a problem that make sex a
problem.
—Respondent 574, 54-year-old treated with surgery
3. I have been, or at least have felt, less attractive sexually.
—Respondent 557, 64-year-old treated with surgery
4. Since surgery, my ED means we need to discover other ways
to have sex that I enjoy, and this takes time and patience.
Being anal receptive is good, but I don’t want to do that all the
time. I really miss having ejaculate when I masturbate to
orgasm, too.
—Respondent 561, 69-year-old treated with surgery
5. Loss of libido, loss of erections, partner doesn’t know how to
help—is intimidated by my condition.
—Respondent 545, 69-year old-treated with external beam
radiation
6. Lack of energy in general. . . with the great decrease in the
amount of semen ejaculated, orgasms do not have the same
sensation/pleasure.
—Respondent 537, 56-year-old treated with brachytherapy
N = 45
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with other samples [28]. In addition, HIV rates
were relatively low at 7%; slightly lower than the
U.S. incidence rate of 11% for men aged over 50
years [29]. Therefore, this cohort does not appear
to possess worse overall health compared with
other research samples. This suggests that an
examination of social-contextual factors, such as
trust in one’s healthcare provider and social
support, will be essential to understanding treat-
ment dissatisfaction as well as the lower levels of
HRQOL among GMPCa.
Other unique factors may contribute to the
observed decrements in functioning and HRQOL.
It is well established that the sexual practices of gay
men differ from that of heterosexual counterparts,
and that sexual “role” can become a signiﬁcant
component of one’s identity [30]. For example,
80% of men who reported being solely in the
insertive sexual role prior to PCa treatment were
no longer in that role posttreatment. In addition,
prior research has documented the cultural signiﬁ-
cance among gay men around the eroticization of
ejaculate and semen [31]. The lack of ejaculate
posttreatment may also factor into lower HRQOL
levels.
The results of our study and the other recent
studies of HRQOL for gay men with PCa have
several implications for urologists and other sexual
health providers. Sexual rehabilitation may be
especially challenging physiologically and difﬁcult
emotionally for gay men. The need for a ﬁrmer
erection for anal penetration may mean that pro-
viders should educate survivors about the limita-
tions of oral therapies for ED and consider more
invasive treatments sooner with gay men. Frank
conversations about possible difﬁculties with
receptive anal sex are also needed. Importantly,
appropriate referrals for evaluation and treatment
should be made, particularly for survivors treated
with radiotherapy. Because of the eroticization of
ejaculation for many gay men as a sign of sexual
completion [30,31], treatment for PCa is inher-
ently distressing because their ejaculation likely
will be impossible after treatment. Sex therapists
can help gay men experiencing distress from
changes in sexual functioning, including loss of
ejaculation, and other physical or psychosocial dif-
ﬁculties. Sex therapists may also be important
resources to help men grieve for their loss of key
aspects of their sexual identity and diminished
spontaneity because of their PCa treatment [32].
Changing from being the insertive partner during
sex to being receptive may be acceptable for some
survivors, but one study suggests that this is prob-
lematic for others [10]. Moreover, sex therapists
can assist survivors in rethinking their options for
a fulﬁlling sexual relationship and deciding what
adjustments they may be willing to make.
Limitations of the current study include a
highly self-selected, small sample, cross-sectional
design, and lack of information about physician–
patient relationships. The clinical data were gath-
ered via self-report, which may not reﬂect the
actual clinical records and resulted in more
missing data than studies that have the ability to
extract information from patient records.
Although we compared our ﬁndings against other
North American published samples that were
comparable regarding age and time since diagno-
sis, the samples were not perfectly matched.
Ideally, future studies should recruit an age and
treatment-matched heterosexual sample of men as
a comparator. Our sample was comprised primar-
ily of self-identiﬁed, highly educated Caucasian
men comfortable being “out” as gay, and willing to
complete an online survey. Given that “outness”
and higher education have both been shown to
predict better physical and mental health out-
comes, our data may underestimate the problems
faced by older men who were raised in an era
where being gay or bisexual was less socially
acceptable. As social norms continue to change for
gay men, future cohorts of GMPCa may experi-
ence less psychosocial burden than was reported in
our sample. Conversely, GMPCa with lower
HRQOL or who were particularly unhappy with
their treatment may be more likely to frequent
support groups or participate in listservs, and
therefore more likely to participate in this
study. Finally, we did not collect data on time since
treatment (patients were, on average, 1.9 years
postdiagnosis) and cannot comment on how this
variable might have affected patient-reported
outcomes.
Conclusions
In summary, this study provides additional data
about changes in sexual functioning and bother
and novel data on the psychosocial aspects of
sexual health after PCa for gay men. Our data
suggest that further research using both validated
psychosocial questionnaires to explore topics such
as anxiety, depression, and grief after treatment,
and open-ended questions to understand how the
experience of GMPCa may be different in yet-
unidentiﬁed ways.
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GMPCa report signiﬁcantly worse HRQOL
and less satisfaction with medical care than other
published samples of men with PCa. Given these
differences, cultural competence at both the indi-
vidual and institutional levels is crucial for
increasing healthcare system responsiveness to
GMPCa [33]. Urologists and other sexual health
providers need to consider the approaches they
use, sensitively inquire as to how the adverse
effects of treatment may differentially affect their
gay or bisexual male patients, and provide clinical
interventions to manage symptoms to assist
GMPCa [4]. When indicated, referral to sex
therapy will help gay men with PCa address the
potentially signiﬁcant experience of sexual losses
and grief due to PCa treatment and achieve a
measure of adaptation to a new sexual paradigm
[4].
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